Patents by Inventor Michaela ALOE

Michaela ALOE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10787491
    Abstract: The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: September 29, 2020
    Assignee: Pieris Pharmaceuticals GmbH
    Inventors: Marlon Hinner, Andrea Allersdorfer, Rachida Siham Bel Aiba, Michaela Aloe, Alexander Wiedenmann, Gabriele Matschiner, Martin Huelsmeyer
  • Publication number: 20190309037
    Abstract: The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.
    Type: Application
    Filed: April 19, 2019
    Publication date: October 10, 2019
    Inventors: Marlon Hinner, Andrea Allersdorfer, Rachida Siham Bel Aiba, Michaela Aloe, Alexander Wiedenmann, Gabriele Matschiner, Martin Huelsmeyer
  • Patent number: 10273275
    Abstract: The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: April 30, 2019
    Inventors: Marlon Hinner, Andrea Allersdorfer, Rachida Siham Bel Aiba, Michaela Aloe, Alexander Wiedenmann, Gabriele Matschiner, Martin Huelsmeyer
  • Publication number: 20180141988
    Abstract: The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.
    Type: Application
    Filed: May 18, 2016
    Publication date: May 24, 2018
    Applicant: Pieris Pharmaceuticals GmbH
    Inventors: Marlon HINNER, Andrea ALLERSDORFER, Rachida Siham BEL AIBA, Michaela ALOE, Alexander WIEDENMANN, Gabriele MATSCHINER, Martin HUELSMEYER